Kei Takuma

451 total citations
34 papers, 248 citations indexed

About

Kei Takuma is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Kei Takuma has authored 34 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hepatology, 14 papers in Epidemiology and 8 papers in Molecular Biology. Recurrent topics in Kei Takuma's work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Liver Disease Diagnosis and Treatment (12 papers) and Liver Disease and Transplantation (8 papers). Kei Takuma is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Liver Disease Diagnosis and Treatment (12 papers) and Liver Disease and Transplantation (8 papers). Kei Takuma collaborates with scholars based in Japan, China and United States. Kei Takuma's co-authors include Tsutomu Masaki, Koji Fujita, Asahiro Morishita, M. Nakahara, Tomoko Tadokoro, Kyoko Oura, Joji Tani, Takashi Himoto, Tingting Shi and Hirohito Yoneyama and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Kei Takuma

28 papers receiving 248 citations

Peers

Countries citing papers authored by Kei Takuma

Since Specialization

Citations

This map shows the geographic impact of Kei Takuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Takuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Takuma more than expected).

Fields of papers citing papers by Kei Takuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Takuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Takuma. The network helps show where Kei Takuma may publish in the future.

Co-authorship network of co-authors of Kei Takuma

This figure shows the co-authorship network connecting the top 25 collaborators of Kei Takuma. A scholar is included among the top collaborators of Kei Takuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kei Takuma. Kei Takuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Galectins and Liver Diseases 2025 ·International Journal of Molecular Sciences ·Shima Mimura, Asahiro Morishita, Kyoko Oura, Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara	2
2	Do Patients With Alcoholic Cirrhosis Accurately Recognize Their Alcohol Tolerance? A Study Comparing Self‐Perception and ALDH2/ADH1B Genotype 2025 ·Hepatology Research ·Tomoko Tadokoro, (unknown), Hung Tai, (unknown), Kei Takuma, Kyoko Oura, Koji Fujita, Shima Mimura, Joji Tani, Asahiro Morishita, Nobuyuki Miyatake, (unknown), Kenji Kinoshita, Hideki Kobara	0
3	A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index 2025 ·Diagnostics ·Tomoko Tadokoro, Miwa Kawanaka, Kazuhiro Takahashi, Shinichi Aishima, (unknown), (unknown), Kei Takuma, M. Nakahara, Kyoko Oura, Koji Fujita, Kiyoyuki Kobayashi, Shima Mimura, Joji Tani, Asahiro Morishita, Reiji Haba, Tsutomu Masaki, Hideki Kobara, Masafumi Ono	0
4	Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration 2025 ·Clinical and Translational Science ·Koji Fujita, Kei Takuma, Kyoko Oura, Tomoko Tadokoro, Asahiro Morishita, Takashi Himoto, Hideki Kobara	0
5	Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism 2025 ·Internal Medicine ·Tomoko Tadokoro, Joji Tani, (unknown), (unknown), Kei Takuma, (unknown), Kyoko Oura, Koji Fujita, Masafumi Ono, (unknown), (unknown), Takuya Inoue, Asahiro Morishita, Hideki Kobara	0
6	Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma 2025 ·Journal of Gastroenterology ·Kyoko Oura, Asahiro Morishita, (unknown), (unknown), Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, (unknown), Takashi Himoto, (unknown), Hideki Kobara	1
7	Efficiency of Skeletal Muscle Mass/Weight Measurement for Distinguishing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Analysis Using InBody Bioimpedance Devices 2024 ·Nutrients ·(unknown), (unknown), (unknown), (unknown), Akemi Gálvez, Ichiro Ishikawa, Yu Nakamura, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Asahiro Morishita, Takashi Himoto, S Miyazaki, (unknown), Yoshihiro Mori, (unknown), Hideki Kobara	2
8	Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients 2024 ·BMC Gastroenterology ·Tomoko Tadokoro, Takako Nomura, Koji Fujita, (unknown), Kei Takuma, (unknown), Kyoko Oura, Shima Mimura, Joji Tani, Asahiro Morishita, Hideki Kobara, (unknown), Tsutomu Masaki	1
9	Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis 2024 ·Scientific Reports ·Tomoko Tadokoro, Joji Tani, (unknown), Kei Takuma, M. Nakahara, Kyoko Oura, Shima Mimura, Koji Fujita, Takako Nomura, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Masafumi Ono, Tsutomu Masaki	6
10	Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival 2023 ·Cancer Medicine ·Kyoko Oura, Asahiro Morishita, Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Masafumi Ono, Takashi Himoto, Tsutomu Masaki	2
11	Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease 2023 ·Diagnostics ·(unknown), Chikara Ogawa, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, (unknown), Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki	10
12	Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy 2023 ·Cancers ·Kyoko Oura, Asahiro Morishita, (unknown), Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, (unknown), Chikara Ogawa, Akio Moriya, (unknown), Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Takashi Himoto, Tsutomu Masaki	7
13	Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy 2023 ·Cancers ·Kyoko Oura, Asahiro Morishita, Joji Tani, Takako Nomura, (unknown), Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, (unknown), Yoshihiro Nishiyama, Tsutomu Masaki	4
14	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines 2022 ·International Journal of Molecular Sciences ·Kei Takuma, Shintaro Fujihara, Koji Fujita, Hisakazu Iwama, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Joji Tani, Tingting Shi, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Tsutomu Masaki	3
15	Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study 2022 ·Hepatology International ·Asahiro Morishita, Kyoko Oura, Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Tingting Shi, Takashi Himoto, (unknown), Akio Moriya, (unknown), Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Masafumi Ono, Tsutomu Masaki	23
16	Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model 2022 ·PLoS ONE ·Asahiro Morishita, Tomoko Tadokoro, Shintaro Fujihara, Hisakazu Iwama, Kyoko Oura, Koji Fujita, Joji Tani, Kei Takuma, M. Nakahara, Tingting Shi, Reiji Haba, Keiichi Okano, Akira Nishiyama, Masafumi Ono, Takashi Himoto, Tsutomu Masaki	9
17	Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells 2022 ·Anticancer Research ·(unknown), Shintaro Fujihara, Hisakazu Iwama, Koji Fujita, Tingting Shi, (unknown), (unknown), Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Joji Tani, Asahiro Morishita, Hideki Kobara, Masafumi Ono, Takashi Himoto, Tsutomu Masaki	6
18	Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells 2021 ·International Journal of Molecular Sciences ·Tingting Shi, Hisakazu Iwama, Koji Fujita, Hideki Kobara, Noriko Nishiyama, Shintaro Fujihara, (unknown), Hirohito Yoneyama, Asahiro Morishita, Joji Tani, (unknown), M. Nakahara, Kei Takuma, Tsutomu Masaki	27
19	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study 2021 ·Cancers ·Joji Tani, Tomonori Senoh, Akio Moriya, Chikara Ogawa, Akihiro Deguchi, Teppei Sakamoto, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Koji Fujita, Hirohito Yoneyama, Hideki Kobara, Asahiro Morishita, Takashi Himoto, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Tsutomu Masaki	5
20	Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg 2021 ·Internal and Emergency Medicine ·Shima Mimura, Koji Fujita, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Hideki Kobara, Joji Tani, Asahiro Morishita, Takashi Himoto, Tsutomu Masaki	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact